Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its weight-loss and diabetes drugs.
Novo Nordisk Posts Mixed Results, Adding to Jitters About Weight-Loss Drugs
Ozempic sales were a bit lower than expected in the quarter at DKK 29.8 billion, while Wegovy sales were higher at DKK 17.3 billion. The obesity drug market is currently dominated
Wegovy sales are slaying for Novo Nordisk right now
Sales of Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy continue to soar, surpassing Wall Street expectations. The Danish pharma giant posted its third-quarter earnings report early Tuesday morning and boasted sales figures blowing past analysts’ projections.
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.
Novo Nordisk Stock Slips as Sales Grow Less Than Expected
After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of estimates despite continued growth form weight-loss drugs Ozempic and Wegovy.
Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a red-hot market hinges on it.
Novo Nordisk expects high demand for its obesity drugs in India, says country head
Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when launched in India, a top executive said.The company is still "evaluating" the price of the drug,
Novo Nordisk’s Blockbuster Wegovy Drug Sales Beat Expectations
The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year growth guidance.
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.
Novo Nordisk’s Wegovy Sales Increase Reassures Investors
Novo Nordisk A/S posted surging sales of its blockbuster weight-loss treatment Wegovy, reassuring investors after rival Eli Lilly & Co. reported disappointing sales of its obesity treatment last week.
healthday1h
Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss ...
Fortune on MSN2d
Danish town where weight-loss wonder drug Ozempic is made suffers from the highest rates of overweight children in Denmark
A more tragic irony in the town is an obesity crisis among residents living in the shadow of the massive Wegovy-making plant.